Publications by authors named "A Provenzano"

Introduction: Despite an improved understanding of its pathogenesis, dry eye disease (DED) remains relatively underestimated and its treatment challenging. A better alignment between the clinical evaluation and the patient self-assessment also requires capturing the whole patient experience of DED. This project aimed to unveil this experience through narrative medicine (NM).

View Article and Find Full Text PDF
Article Synopsis
  • - The Q&A details the latest updates and recommendations from ASCO (American Society of Clinical Oncology) on systemic therapy options for treating melanoma.
  • - It addresses common questions and concerns healthcare providers may have about the guideline's implementation in clinical practice.
  • - The document aims to improve patient outcomes by providing clear, evidence-based information on the most effective treatment strategies for melanoma.
View Article and Find Full Text PDF

(1) Background: Innovation and continuous demand in the field of visual enhancing technologies and video streaming have led to the discovery of new systems capable of improving visualization and illumination of the surgical field. The exoscope was brought into neurosurgical routine, and nearly ten years later, modern 3D systems have been introduced and tested, giving encouraging results. (2) Methods: In order to evaluate the surgeon's confidence with the exoscope and their increasing ability in terms of time spent and quality of the final achievement since their first encounter with the technique, an experimental trial on 18 neurosurgeons from a single Institution was performed to evaluate the learning curve for the use of the VITOM-3D exoscope in neurosurgical practice on a model of brain and dura mater.

View Article and Find Full Text PDF
Article Synopsis
  • The article provides updated guidelines for clinicians on systemic therapy options for melanoma, based on a systematic review by the American Society of Clinical Oncology Expert Panel.
  • New recommendations include using neoadjuvant pembrolizumab for resectable stage IIIB to IV melanoma, and adjuvant nivolumab or pembrolizumab for stage IIB-C disease.
  • Additionally, certain older treatments are no longer recommended for specific melanoma types, and new options are suggested for unresectable or metastatic cases.
View Article and Find Full Text PDF